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Abstract
177Lu-DOTA-HH1 (177Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to
treat non-Hodgkin lymphoma. Mice with subcutaneous Ramos xenografts were treated with
different activities of 177Lu-HH1, 177Lu-DOTA-rituximab (177Lu-rituximab) and non-specific
177Lu-DOTA-IgG1 (
177Lu-IgG1) and therapeutic effect and toxicity of the treatment were
monitored. Significant tumor growth delay and increased survival of mice were observed in
mice treated with 530 MBq/kg 177Lu-HH1 as compared with mice treated with similar activi-
ties of 177Lu-rituximab or non-specific 177Lu-IgG1, 0.9% NaCl or unlabeled HH1. All mice in-
jected with 530 MBq/kg of 177Lu-HH1 tolerated the treatment well. In contrast, 6 out of 10
mice treated with 530 MBq/kg 177Lu-rituximab experienced severe radiation toxicity. The re-
tention of 177Lu-rituximab in organs of the mononuclear phagocyte system was longer than
for 177Lu-HH1, which explains the higher toxicity observed in mice treated with 177Lu-rituxi-
mab. In vitro internalization studies showed that 177Lu-HH1 internalizes faster and to a
higher extent than 177Lu-rituximab which might be the reason for the better therapeutic ef-
fect of 177Lu-HH1.
Introduction
Despite the promise of therapy using the naked monoclonal antibody (mAb) rituximab, a sub-
stantial number of the patients treated with conventional doses of rituximab alone or in combi-
nation with chemotherapy do not obtain complete response and may eventually relapse [1].
Alternative treatments have been anti-CD20 mAbs conjugated to 131I (tositumomab) or 90Y
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(ibritumomab-tiuxetan). Treatment with conventional activities of the radiolabeled mAbs has
produced higher overall response and complete remission rates compared with naked mAbs
[2–5]. Considering that radioimmunotherapy (RIT) is mostly used after patients have been
treated with several rounds of rituximab and that the two approved radioimmunoconjugates
(RICs) for clinical use, 90Y-ibritumomab-tiuxetan (Zevalin) and 131I-tositumomab (Bexxar),
target the same CD20 antigen as rituximab, it is desirable to design a new RIC that will target a
different antigen than CD20. The CD37 antigen is abundantly expressed in B-cells, but is ab-
sent on plasma cells and normal stem cells [6–8]. Therefore, CD37 seems to be an appropriate
therapeutic target in patients with relapsed B-cell derived malignancies, such as B-cell CLL,
hairy-cell leukemia (HCL) and B-cell NHL.
RIT with CD37 as target has previously been explored using a 131I-labeled murine monoclo-
nal antibody (MB-1) both in a mouse model and in patients [9–14]. A higher degree of inter-
nalization and degradation of 131I-labeled RIC was found for CD37 than for CD20 [14].
Despite promising clinical responses observed in these clinical studies for the anti-CD37 anti-
body, further development of RIT focused on CD20 as the target antigen and no subsequent ef-
forts have been made to develop RIT with anti-CD37-based RICs. A limited number of other
CD37-directed antibody based immunotherapies have, however, been evaluated in patients.
The small modular immunopharmaceutical protein Otlertuzumab has advanced into clinical
testing [15] and recently reported on phase II data in combination with bendamustine [16]. In
addition, the Fc-engineered antibody CD37.1 (BI836826) [17] has recently entered phase I
[18]. Furthermore, two antibody-drug conjugates (ADCs) have been developed that covalently
link cytotoxic agents to CD37-targeting antibodies to enhance their antitumor potency:
IMGN529 [19] and AGS-67E [20]. ADCs are designed to give specific delivery of cytotoxic
compounds to cells expressing the target antigen, through ADC binding, internalization, and
intracellular payload release. Clinical data have demonstrated the potential of ADCs for cancer
therapy of CD30 and HER2 positive tumors [21,22]. All these CD37 targeting drugs had
shown promising results, which further validates CD37 as a target for treatment of NHL and
CLL. An advantage with RIT compared with naked mAbs and ADCs is the range of the emitted
radiation, which gives a cross-fire effect so that tumor cells with less antigens or non-accessible
tumor cells also get hit by the cytotoxic radiation. It remains to be seen if the mechanism of ac-
tion of RIT is better than that of ADCs.
The potency of RIT against the internalizing antigen CD37 might have been underesti-
mated by the use of the radionuclide 131I, which tends to be cleaved off from the antibody
and excreted from the cells upon internalization and catabolism when used as “non-residua-
lizing” tyrosine-incorporated radiolabel, as was done in the early studies with 131I-MB-1 [23].
“Residualizing” radiolabels, on the other hand, are trapped in the cells after metabolism of
the RIC. In an effort to re-evaluate and improve RIT against CD37 we have developed a new
RIC (Betalutin) based on the “residualizing” radiolabel 177Lu linked to the anti-CD37 anti-
body HH1 [24]. Treatment with 100 MBq/kg 177Lu-HH1 resulted in a threefold increase in
the survival of SCID mice that were intravenously injected with Daudi lymphoma cells com-
pared to untreated control mice [7]. SCID mice are not able to repair DNA double strand
breaks [25], limiting the amount of radioactivity that can be administered, while nude mice
can tolerate higher doses of radiation. A subcutaneous tumor xenograft in nude mice is a
more relevant model for the bulky type of disease that is often found in NHL patients
than the intravenous model in SCID mice. Therefore, the therapeutic and toxicity effect of
177Lu-HH1 was evaluated in nude mice with subcutaneous Ramos xenografts in the present
paper.
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Materials and Methods
Tumor cells
Ramos lymphoma cells (LGC Standards, Boras, Sweden) expressing the CD20 and CD37 re-
ceptors were grown in RPMI 1640 medium supplemented with Glutamax (Gibco, Paisley,
UK), 10% heat-inactivated FCS (Gibco) and 1% penicillin-streptomycin (Gibco) in a humid at-
mosphere with 95% air/5% CO2.
Radiolabeling of antibodies
The antibodies HH1 (anti-CD37, Nordic Nanovector ASA, Oslo, Norway), Rituximab (anti-
CD20, Roche, Pharma Schweiz, Basel, Switzerland) and the murine non-specific isotype con-
trol antibody (IgG1) (MAB002, R&D Systems Inc., Minneapolis, USA) were labeled with the
chelator p-SCN-Bn-DOTA (DOTA, Macrocyclics, TX, USA) and subsequently labeled with
177Lu (ITG, Garching, Germany) as previously described [26]. Labeling with 125I (Hartmann
Analytic, Braunschweig, Germany) was performed using iodogen tubes (Pierce, Rockford, IL,
USA) as described previously [23].
The immunoreactivity (IRF) of all the tumor specific RICs was verified using a modified
Lindmo method [27] with one cell concentration of 75 million cells/ml. The IRF of all specific
RICs was between 57% and 76%.
Number of cell surface receptors
Scatchard analyses were performed using 177Lu-HH1 or 125I-rituximab. A concentration of 10
million cells/ml of Ramos lymphoma cells were incubated for 1 hour with increasing amounts
of radioimmunoconjugates (between 0 and 6.25 nM). Cells previously blocked with unlabeled
antibody were used to account for non-specific binding. Each sample was measured in dupli-
cates and the results were averaged. After incubation with the RIC, the activity in each sample
was measured using a gamma counter (Cobra gamma; Packard Instrument Co, Meriden, CT,
USA) and cells were washed two times using DPBS (Gibco, Paisley, UK) supplemented with
0.5%wt Bovine Serum Albumin (BDH Prolabo, VWR, Lutterworth, Leicestershire, UK), after
which the activity bound to the cells was counted in the gamma counter. The equilibrium dis-
sociation constant (Kd) and maximum average density of antigens (Bmax) was calculated from
the fitting of the experimental data. Three experiments were performed using 177Lu-HH1 and
2 experiments using 125I-rituximab. The results from all experiments for each RIC were aver-
aged to obtain an average value of Kd and Bmax for each RIC.
Internalization experiments
HH1-DOTA was labeled with Alexa Fluor 488 and rituximab with Alexa Fluor 647 (Molecular
Probes, Invitrogen, Paisley, UK). One million Ramos cells per ml in growth medium were incu-
bated with 10 μg/ml of HH1 or 20 μg/ml of rituximab for either 19 hours at 37°C or 1 h at
around 4°C. Hoechst 33342 (Sigma-Aldrich, St.Louis, MO, US) was added to the cells to a con-
centration of 2 μg/ml 1 hour before imaging. Cells were imaged with an AxioImager Z1 Apo-
Tome microscope system (Carl Zeiss, Jena, DE) using a PlanApo 63×/N.A.1.4 DIC lens,
appropriate optical filters, an AxioCamMRm camera and Axiovision 4.8.2 (Carl Zeiss). Z-sec-
tions were obtained for every 1 μm across the entire cell volume. Images are presented as over-
lays of fluorescence images of central z-section and DIC image. 20 to 40 cells were scanned for
each treatment.
β-Radioimmunotherapy with 177Lu-HH1
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Animals and xenografts
Institutionally bred female Athymic nude FOX1nu mice were used. Age and weight of the mice
are given in Table 1. The animals were maintained under pathogen-free conditions with a 12
hours lighting cycle at a room temperature of 23°C and air relative humidity of 55% in plastic
cages. Food and water were supplied ad libitum and bedding was changed regularly. Mice were
anesthetized with subcutaneous injections of 70–100 μl Tiletamin-Zolazepam mix (Virbac, Car-
ros Cedex, France) diluted 1:5 with sterile water before implantation of pieces of Ramos lym-
phoma xenograft tissue from carrier mice, (diameter 1.5–2 mm) in the flanks. All procedures
and experiments involving animals in this study were approved by The Norwegian Animal Re-
search Authority (NARA). The Department of Comparative Medicine institutional veterinarian
has established the rules for feeding, monitoring, handling, and sacrifice of animals in compli-
ance with regulations set by the Ministry of Agriculture of Norway and “The European Conven-
tion for the Protection of Vertebrate Animals used for Experimental and other Scientific
Purposes”. The institutional veterinarian has delegated authority from the Norwegian Animal
Research Authority (NARA). The laboratory animal facilities are subject to a routine health-
monitoring program and tested for infectious organisms according to a modification of Federa-
tion of European Laboratory Animal Science Associations (FELASA) recommendations.
Therapy and toxicity experiments
Animals bearing growing tumors with diameters between 4 and 12 mm were randomized in
cages according to treatment group and were administered intravenously with 100 μl of injec-
tion solutions adjusted for individual mouse weight. Two preliminary experiments were per-
formed with injection of activities between 50 and 1000 MBq/kg 177Lu-HH1 (S1 File). These
experiments were used to decide the experimental parameters chosen for the two experiments
presented in this paper (Table 1) which included injected activities of 410 and 530 MBq/kg
177Lu-HH1, 300 and 530 MBq/kg 177Lu-rituximab, 530 MBq/kg 177Lu-IgG1 and 15 μg/kg HH1
and 0.9% NaCl as control groups.
The mice were weighed and clinically observed two to three times a week for up to 109 days.
In addition the mice were monitored daily for any sign of illness or discomfort. Activity level,
skin condition (eczema, hemorrhages, etc.) and general health of the mice were observed daily.
Mice were euthanized by cervical dislocation under Sevoflurane gas anesthesia if any of the fol-
lowing humane end points were reached: tumor diameter exceeded 20 mm, body weight de-
creased by 20% from highest body weight or animals otherwise showed symptoms of severe
illness and discomfort.
Tumor growth was monitored up to the first tumor volume measurement higher than 2000
mm3 in each mouse (bigger tumors usually develop necrotic wounds). Complete remission was
Table 1. Overview of therapy and toxicity experiments in nudemice with Ramos xenografts.
Experiment Treatments mice/
group
Mice agea
(weeks)
Mice
weightsb (g)
Tumor volumesb,
(mm3)
1 530 MBq/kg 177Lu-HH1, 530 MBq/kg 177Lu-rituximab, 530 MBq/kg
177Lu-IgG1, 15 μg/kg HH1, 0.9% NaCl
9–10 6–8 21.1–29.0
(25 ± 2)
20–780 (139 ± 134)
2 410 MBq/kg 177Lu-HH1, 300 MBq/kg 177Lu-rituximab, 0.9% NaCl. 5–6 6–8 21.0–29.7
(25 ± 2)
22–760 (342 ± 221)
aAt implantation of xenografts.
bAt treatment injection Min-Max (Average ± SD).
doi:10.1371/journal.pone.0128816.t001
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defined as no observable tumor. Mice reaching this stage were considered as long term
responders.
Hematology. Blood samples were taken prior to injection, at death and every 4 to 7 weeks
after treatment administration. The blood sampling was performed as described previously
[26]. Radiation toxicity was defined as white blood cell counts below 1×109 1/L, platelet counts
below 400×109 1/L, sudden weight loss—around 5% in the lapse of 2 to 3 day- accompanied by
a low activity level, and a general state of sickness. Comparisons between average values of dif-
ferent treatment groups were done using t-tests with a significance level of 0.05.
One mouse treated with 530 MBq/kg 177Lu-HH1 was sacrificed 11 days after treatment in-
jection in order to obtain hematology and histology data at this particular time point. Further-
more, to obtain more hematological data 3 mice having tumor diameters between 12 and 15
mm (800 and 1300 mm3) were also included in experiment 2.
Histopathology. Mice were necropsied and heart, lungs, liver, stomach, spleen, small and
large intestines, kidneys, femur, muscle, skull, brain, tumor, skin, ovaries and lymph nodes
were fixed and shipped to Accelera, Milano, Italy for casting, sectioning, staining and
pathological examination.
Biodistribution experiments
Conjugates were administered by tail vein injection of 100 μl solution (0.2 and 0.9 MBq) to
each animal. Between 4 and 7 mice were sacrificed by neck dislocation under Sevoflurane gas
anesthesia at each time point after cardiac puncture for blood sampling. Tumor sizes at injec-
tion of conjugates varied between 120 and 1800 mm3. Studies were conducted as described in
reference [28]. Comparisons between average values were done using t-tests with a significance
level of 0.05.
A pilot In vivo SPECT/CT was performed on 2 mice with Ramos subcutaneous xenografts
with diameters around 12 mm in their right flank in a nanoSPECT/CT (Bioscan Inc., Washing-
ton DC, USA). SPECT/CT acquisitions were performed at 3, 24 and 48 hours after treatment
injection in mouse 1 and after 24 hours in mouse 2. Activities measured by SPECT/CT were
compared with ex-vivo measurements done at 48 hours after treatment administration. Mice
were injected i.v. with 150 μl of 10 MBq of 177Lu-HH1 and were anaesthetized with 2% Iso-
fluran for image acquisition.
Dosimetry
The dose rate and absorbed doses from 177Lu-HH1 and 177Lu-rituximab in mice were
calculated as described in reference [28] for an injection of 1 MBq/mouse (40 MBq/kg) and
assuming the mean energy of the β-particles, Auger- and conversion electrons to be 0.1473
MeV [29]. The self-radiation fraction for tumor was estimated to be 0.944 (200 mg tumor
[30]).
Statistical analysis
The survival of the different treatment groups was compared by Kaplan-Meyer survival analy-
sis using SigmaPlot for Windows version 12.0 (Systat Software Inc., California, USA) using
time to reach a tumor volume higher than 4 times the initial tumor volume or euthanasia due
to radiation toxicity symptoms as the end points. Hematology and biodistribution data were
compared using one-way ANOVA. Multiple comparisons were performed using the Holm
Sidak method. A significance level of p< 0.05 was used in all tests.
β-Radioimmunotherapy with 177Lu-HH1
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Results
Therapy and toxicity experiments
Tumor growth and survival. There was a marked tumor growth delay in mice treated
with 530 MBq/kg 177Lu-HH1 when compared to mice treated with either 177Lu-IgG1 or 0.9%
NaCl (Fig 1A). Tumor growth was also delayed in some of the mice treated with 530 MBq/kg
177Lu-rituximab, but this treatment proved to be toxic: 60% of the mice had to be sacrificed due
to symptoms of severe radiation toxicity between 11 and 18 days after injection of treatment
(Table 2). None of the mice were sacrificed due to radiation toxicity symptoms in any of the
other treatment groups. Tumor growth in the control mice treated with 0.9% NaCl or 15 μg/kg
naked HH1 was non-homogeneous, with 30% and 10% complete remission, respectively. On
the other hand, tumors in mice treated with 530 MBq/kg 177Lu-IgG1 grew homogeneously and
did not show any natural regressions. The number of long term responders was highest in mice
treated with 530 MBq/kg 177Lu-HH1 (Fig 1B). Furthermore, treatment with 530 MBq/kg
177Lu-HH1 significantly extended the survival of mice compared with 177Lu-IgG1, 0.9% NaCl
and HH1 (p< 0.05) (Fig 1C, Table 2). Survival of mice treated with 177Lu-IgG1 was significant-
ly shorter than for those treated with 0.9% NaCl (p< 0.05), which was due to the growth ho-
mogeneity and the lack of tumor regression observed in mice treated with 177Lu-IgG1, which
might be related to radiation induced immunosuppression. It has been previously shown that
growth of xenografts in mice can be enhanced by whole body irradiation (WBI) [31–34] or
other immunomodulating agents [32,35–38]. Natural regressions of xenografts in nude mice in
control groups have been observed previously [33,35], especially in nude mice with subcutane-
ous Ramos xenografts [39,40]. RIT can be regarded as a type of WBI treatment, which may
therefore result in better take and growth of xenografts in treated mice than in control mice.
Thus, the therapeutic efficacy of RIT might be underestimated in mouse models where total
body irradiation enhances tumor growth, especially when comparing the therapeutic effect of
RICs with agents having low systemic toxicity such as NaCl or unlabeled mAbs. It might be
more convenient, therefore, to compare the effect of RICs to corresponding dosages of non-
specific, control RICs instead.
Given the high toxicity observed during the first two weeks in some of the mice treated with
177Lu-rituximab, one more experiment was performed using lower activities. Treatments with
410 MBq/kg 177Lu-HH1 and 300 MBq/kg 177Lu-rituximab (approximately 50% of the LD50 of
each RIC) resulted in a slight tumor growth delay (Fig 2A). Mice treated with 410 MBq/kg
177Lu-HH1 had the highest number of long term responders while there was no long term re-
sponders in mice treated with 300 MBq/kg 177Lu-rituximab due to no inhibition of tumor
growth (Fig 2B). Median survival was longer in mice treated with 410 MBq/kg 177Lu-HH1
(more than 15 times compared to the control group) but the difference was not statistically sig-
nificant compared with the other treatment groups (p> 0.05) (Fig 2C, Table 2). Median sur-
vival of mice treated with 300 MBq/kg 177Lu-rituximab was around 3 times longer than for the
mice in the control group, while the median survival of mice treated with 530 MBq/kg 177Lu-
rituximab was similar to the mice in the control group. Even when the amount of long term re-
sponders was higher for the higher injected activity of 177Lu-rituximab the toxicity of the treat-
ment had a strong impact on the median survival. The optimal injected activity for 177Lu-
rituximab might lie in between 300 and 530 MBq/kg, where an optimal amount of long term
responders could be found without life-threatening toxicity.
Body weight. The average body weight of mice treated with RICs decreased sharply after
injection. The average body weight loss lasted for around 7 days for treatment with 530 MBq/
kg and around 4 days for treatment with 410 and 300 MBq/kg activities (Fig 3). Afterwards, the
β-Radioimmunotherapy with 177Lu-HH1
PLOSONE | DOI:10.1371/journal.pone.0128816 June 11, 2015 6 / 19
Fig 1. Tumor growth, long term responders and survival of nudemice with Ramos xenografts after
treatment with 530 MBq/kg 177Lu-HH1, 530 MBq/kg 177Lu-rituximab, 530 MBq/kg 177Lu-IgG1 non-
specific isotype control, 15 μg/kg HH1 and 0.9% NaCl. (A) Individual tumor growth (n = Number of tumors
β-Radioimmunotherapy with 177Lu-HH1
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average body weight of the treated mice began to increase, tending toward the average body
weight of the control groups.
Hematology. The average numbers of White Blood Cells (WBC) and Red Blood Cells
(RBC) for mice treated with 530 MBq/kg of the different RICs were below the values for the
NaCl control group for 4 and 8 weeks but normalized at the end of the study (Fig 4A). The av-
erage number of platelets (PLT) did not vary significantly between treatment and control
groups. However, between 11 and 25 days after treatment with RICs, WBC, RBC and PLT
numbers were considerably lower in mice treated with 530 MBq/kg, indicating a nadir around
2 weeks after treatment administration. There were no control animals sacrificed in this time
range, but control values can be assumed to be close to those measured at baseline and around
4 weeks after treatment injection in the NaCl group.
The average number of WBC in mice treated with 410 MBq/kg 177Lu-HH1 and 300 MBq/
kg 177Lu-rituximab was significantly lower than for the control group 4 weeks after treatment
administration, but the values normalized towards the end of the experiment (Fig 4B). The av-
erage number of RBC and PLT were similar for all treatment groups (p> 0.05). There were no
deaths associated to severe symptoms of radiation toxicity in this experiment. However, WBC
counts in mice treated with 177Lu-rituximab that were sacrificed at 13 and 17 days due to
tumor diameter higher than 20 mm hadWBC, RBC and PLT values considerably lower than
the values measured for NaCl at similar time points.
Histopathology. The main organs affected by treatment with RICs with activities equal to
or higher than 530 MBq/kg were the bone marrow, lymph nodes, spleen and ovaries. Animals
treated with 530 MBq/kg 177Lu-rituximab showed severe changes in hemato-lymphopoietic tis-
sues, including decreased extra-medullary hematopoiesis, lymphoid depletion in the spleen
and atrophy of the bone marrow (Fig 5A), indicating radiation damage (Table 3). These obser-
vations were more severe the sooner the mice had to be sacrificed after treatment injection.
in remission at the end of study/total number of initial tumors); (B) Percentage of long term responders (mice
euthanized due to radiation toxicity symptoms or for hematology measurements before one of their tumors
reached a volume of 2000 mm3 were not considered in the analysis); (C) Kaplan-Meier survival curve. End
point: tumor volume 4 times initial tumor volume. Crosses represent censored animals that were
euthanized before reaching 4 times the initial tumor volume. N = 9–10. Multiple comparisons were performed
using Holm Sidak method. Significance level: p < 0.05.
doi:10.1371/journal.pone.0128816.g001
Table 2. Median survival time of mice and percentage of mice euthanized due to radiation toxicity after treatment with 530 MBq/kg 177Lu-HH1,
177Lu-rituxmab and 177Lu-IgG1 non-specific isotype control, HH1 or NaCl.
Experiment Group Median survival time ± SE (days) Radiation Toxicity (%)
1 NaCl 18 ± 3a 0
HH1 15 μg/kg 11 ± 2a 0
530 MBq/kg 177Lu-IgG1 7 ± 1a 0
530 MBq/kg 177Lu-rituximab 18 ± 4 60
530 MBq/kg 177Lu-HH1 > 109 0
2 NaCl 6 ± 3 0
300 MBq/kg 177Lu-rituximab 17 ± 3 0
410 MBq/kg 177Lu-HH1 > 97 0
aSigniﬁcantly different from 177Lu-HH1 (p < 0.05).
doi:10.1371/journal.pone.0128816.t002
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Similar observations were made for treatments with 800 and 1000 MBq/kg of 177Lu-HH1 [26].
Most of the mice showing severe radiation toxicity symptoms also presented skin hemorrhages
(Fig 5B) that started as a skin rash a few days before euthanasia. The histopathology observa-
tions were in good agreement with the hematology measurements. For activities of 530 MBq/
kg and higher ovaries were affected [26]. Mice euthanized between 11 to 25 days after treat-
ment administration did, however, not show abnormalities in the ovaries, indicating that these
lesions take more than 3 weeks to develop.
Fig 2. Tumor growth, long term responders and survival of nudemice with Ramos xenografts after
treatments with 410 MBq/kg 177Lu-HH1, 300 MBq/kg 177Lu-rituximab and 0.9% NaCl. (A) Individual
tumor growth (n = Number of tumors in remission at the end of study/total number of initial tumors) (B)
Percentage of long term responders; (C) Kaplan-Meier survival curve. End point: tumor volume 4 times
initial tumor volume. Crosses represent censored animals that were euthanized before reaching 4 times the
initial tumor volume. N = 5–6. Multiple comparisons were performed using Holm Sidak method. Significance
level: p < 0.05.
doi:10.1371/journal.pone.0128816.g002
β-Radioimmunotherapy with 177Lu-HH1
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Biodistribution and dosimetry
Blood clearance was slightly faster for 177Lu-rituximab than for 177Lu-HH1 (Fig 6A), which
gave an absorbed dose to blood in mice treated with 177Lu-rituximab around half of that for
177Lu-HH1 (Table 4, Fig 6B). The retention of 177Lu-rituximab in liver, spleen and femur was
significantly longer than that of 177Lu-HH1 or 177Lu-IgG1 (Fig 6A and 6B) and consequently
absorbed doses to these organs were 2–3 times higher for treatment with 177Lu-rituximab than
for 177Lu-HH1. The higher uptake of 177Lu-rituximab in femur (Table 4) probably resulted in a
Fig 3. Average Body weight. Average body weight of nude mice with Ramos xenografts treated with 530
MBq/kg 177Lu-HH1, 530 MBq/kg 177Lu-rituximab, 530 MBq/kg 177Lu-IgG1 non-specific isotype control, 15 μg/
kg HH1, NaCl 0.9%, 410 MBq/kg 177Lu-HH1 and 300 MBq/kg 177Lu-rituximab.
doi:10.1371/journal.pone.0128816.g003
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higher absorbed dose to red marrow, which is consistent with the higher toxicity and reduced
bone marrow cellularity observed in mice treated with 177Lu-rituximab. The uptake in tumor
was faster for 177Lu-rituximab, but the retention was shorter (not statistically significant,
p> 0.05) than for 177Lu-HH1 (Fig 6A). The absorbed doses to tumor were close to 2 Gy for
both 177Lu-HH1 and 177Lu-rituximab (Table 4). The uptake and retention of 177Lu-HH1 and
177Lu-IgG1 control were similar for all organs/tissues except for kidneys and tumor (Fig 6A).
SPECT/CT images showed a high and heterogeneous tumor uptake compared with other
tissues 48 hours after injection of 177Lu-HH1 (Fig 6C). Uptake in lungs, heart and aorta was
high 3 hours after injection and decreased with increasing time, being considerably reduced
after 48 hours. Uptake in tumor was low 3 hours after 177Lu-HH1 administration but in-
creased with time and was higher than in other tissues after 48 hours. The difference of
tumor uptake measured by SPECT and gamma counter was below 10%, which shows good
agreement between measurements performed in vivo with SPECT and ex vivo by gamma
counting.
Fig 4. Hematology. Number of white blood cells (WBC), red blood cells (RBC) and platelets (PLT) in mice
with Ramos xenografts treated with 530 MBq/kg 177Lu-HH1, 530 MBq/kg 177Lu-rituximab, 530 MBq/kg 177Lu-
IgG1 non-specific isotype control, 15 μg/kg HH1, 0.9% NaCl (A) and 410 MBq/kg
177Lu-HH1 and 300 MBq/kg
177Lu-rituximab (B). The area of each circle represents the number of mice used to calculate the average
values. Circles with dark rim and connected with lines represent samples taken at fixed time points during the
study where all alive mice were sampled. Circles without dark rim and not connected by lines represent blood
samples taken before euthanasia, where usually one or two mice were sacrificed. N = 1–10. Error
bars = standard error. *: Significantly different from the corresponding 0.9% NaCl (control) group value (One-
way ANOVA with Holm Sidak method for multiple comparisons, p < 0.05).
doi:10.1371/journal.pone.0128816.g004
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Fig 5. Histopathology. (A) Representative pictures of: a normal bone marrow from a mouse in the NaCl
group (euthanized 109 days after treatment), marked reduced cellularity in a mouse treated with 530 MBq/kg
177Lu-HH1 euthanized 11 days after treatment, moderate reduced cellularity in a mouse treated with 530
MBq/kg 177Lu-IgG1 euthanized 25 days after treatment and severe reduced cellularity in a mouse treated with
530 MBq/kg 177Lu-rituximab euthanized 15 days after treatment. (B) Example of a mouse with severe skin
hemorrhages 11 days after administration with 530 MBq/kg 177Lu-rituximab. The mouse was sacrificed the
day the pictures were taken.
doi:10.1371/journal.pone.0128816.g005
Table 3. Incidence of main histological findings in nudemice with Ramos xenografts treated with 530 MBq/kg 177Lu-HH1, 177Lu-rituxmab and
177Lu-IgG1 non-specific isotype control or 0.9% NaCl.
Incidence (% (number of mice affected/total number of mice))
Organ Histological ﬁnding NaCl 530 MBq/kg 177Lu-HH1 530 MBq/kg 177Lu-rituximab 530 MBq/kg 177Lu-IgG1
Bone marrow Reduced cellularity 0 (0/10) 11 (1/9) 60 (6/10) 30 (3/10)
Colon Lymphoid depletion 0 (0/9) 0 (0/9) 30 (3/10) 30 (3/10)
Ileum Lymphoid depletion 0 (0/10) 11 (1/9) 10 (1/10) 10 (1/10)
Liver Extramedullary hematopoiesis 0 (0/10) 0 (0/9) 0 (0/10) 40 (4/10)
Inﬂamatory cell inﬁltration 50 (5/10) 11 (1/9) 10 (1/10) 0 (0/10)
Ovaries Atretic follicles (present) 0 (0/10) 89 (8/9) 40 (4/10) 100 (8/8)
Intersticial cell hyperplasia 0 (0/10) 78 (7/9) 40 (4/10) 50 (4/8)
Spleen Extramedullary hematopoiesis 100 (10/10) 89 (8/9) 40 (4/10) 100 (10/10)
Lymphoid depletion 10 (1/10) 22 (2/9) 60 (6/10) 80 (8/10)
Pigmented macrophages 0 (0/10) 11 (1/9) 60 (6/10) 10 (1/10)
doi:10.1371/journal.pone.0128816.t003
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Fig 6. Biodistribution and dosimetry. (A) Uptake of 177Lu-HH1 (N = 6–8), 177Lu-rituximab (N = 4–5), 177Lu-
IgG1 control (N = 5) in selected organs/tissues from nude mice with Ramos xenografts in percentage of
β-Radioimmunotherapy with 177Lu-HH1
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Internalization experiments
HH1 was almost completely internalized after 19 hours of incubation at 37°C, while there was
no significant internalization after 1 hour incubation at 4°C. Some cells showed HH1 both on
the cell surface and inside the cytoplasm while others only showed HH1 inside the cells after 19
hours at 37°C. A small degree of internalization of rituximab was observed after 19 hours of in-
cubation at 37°C, while there was no sign of internalization after 1 hour incubation at 4°C. Fig
7 shows representative images of the cells.
Binding experiments
The number of CD37 antigens per Ramos cell (Bmax) was half the number of CD20 antigens
(Table 5). The dissociation constant (Kd) of HH1 was lower than that of rituximab but the dif-
ference was not statistically significant.
Discussion
The majority of the NHL patients nowadays receive anti-CD20 mAbs as first line treatment.
The first two RICs on the market, Zevalin and Bexxar, also targeted the same antigen. It has
been shown that shaving or downregulation of the CD20 antigen might be a reason for resis-
tance to rituximab [41–43] and it may also be the case for other CD20 based treatments. From
a clinical perspective, it is plausible to use another target than CD20 for second line treatment,
such as the CD37 antigen. There are currently four drug candidates, in addition to 177Lu-HH1,
that target the CD37 antigen: an antibody-based protein [15], an Fc-engineered mAb[17] and
two ADCs [19,20]. Given the heterogeneous vascularization and antigen expression normally
found in tumors [44,45] it might be useful to develop a treatment that possess cross-fire contri-
bution. We have therefore developed a new RIC (Betalutin) based on 177Lu linked to the anti-
CD37 antibody HH1 [24]. The β-emissions of 177Lu have a mean range of 0.67 mm and are
able to reach and kill even those cells to which the RIC is not able to bind. A series of pre-clini-
cal studies have shown that 177Lu-HH1 successfully binds to both lymphoma cell lines and bi-
opsies from NHL patients, indicating that targeting of the CD37 antigen with HH1 is clinically
injected activity per gram of tissue (%IA/g). Error bars = standard error. *: Significantly different from 177Lu-
HH1 (One-way ANOVA with Holm Sidak method for multiple comparisons, p < 0.05). (B) Dose rate per MBq
of injected activity in selected organs of nude mice with Ramos xenografts treated with 177Lu-HH1 (N = 6–8)
and 177Lu-rituximab (N = 4–5). (C) In vivo SPECT/CTmultiplanar rendered view of a nude mouse with a
Ramos xenograft in its right flank injected with 10 MBq of 177Lu-HH1.
doi:10.1371/journal.pone.0128816.g006
Table 4. Absorbed radiation doses per injected MBq and tumor to normal tissues ratios in selected organs of nudemice with Ramos xenografts
administered with 177Lu-HH1 and 177Lu-rituximab.
Dose (Gy/MBq) Tumor/Normal Tissue
Organ/Tissue 177Lu-HH1 177Lu-rituximab 177Lu-HH1 177Lu-rituximab
Blood 1,26 ± 0,06 0,72 ± 0,1 1,7 ± 0,2 2,5 ± 0,5
Liver 0,71 ± 0,05 1,4 ± 0,1 2,9 ± 0,4 1,3 ± 0,2
Spleen 0,54 ± 0,01 1,3 ± 0,3 3,8 ± 0,5 1,3 ± 0,26
Kidney 0,36 ± 0,01 0,36 ± 0,03 5,8 ± 0,8 5,0 ±- 0,9
Femur 0,093 ± 0,001 0,15 ± 0,02 22,3 ±- 3,0 12,0 ±- 2,4
Tumor 2,1 ± 0,3 1,8 ± 0,3 ——- ——-
doi:10.1371/journal.pone.0128816.t004
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relevant [7]. Furthermore, the biodistribution of 177Lu-HH1 was found to be relevant for the
treatment of NHL in SCIDmice i.v. injected with Daudi lymphoma cells and in nude mice with
Daudi [28] and Ramos subcutaneous xenografts as shown in Fig 6. In addition, in vivo experi-
ments in SCIDmice showed that 177Lu-HH1 had a strong therapeutic effect, increasing the sur-
vival of treated mice compared with mice treated with unlabeled HH1 and NaCl [7]. The current
study shows that 177Lu-HH1 has strong antitumor activity and lower toxicity compared with
177Lu-rituximab in nude mice with subcutaneous Ramos xenografts. Even though Ramos cells
had a higher expression of CD20 than CD37, the absorbed doses to tumor for 177Lu-HH1 and
177Lu-rituximab were similar, which might be related to the higher internalization of the
CD37-HH1 complex than of the CD20-rituximab, as observed in vitro. It has been reported pre-
viously that human cells are highly heterogeneous in their ability to internalize CD20 when
bound to mAbs [46], ranging from lack of internalization [8,47–49] to high internalization [50–
53]. The higher myelotoxicity of 177Lu-rituximab than of 177Lu-HH1might be explained by a
higher uptake and retention of 177Lu-rituximab in the bone marrow as indicated by the higher
uptake and retention in the femur, spleen and liver (Fig 6). The higher uptake and retention of
Fig 7. Internalization.Representative images of internalization of HH1 and Rituximab in Ramos cells after
incubation with 10 μg/ml of HH1 or 20 μg/ml rituximab at 4°C or 37°C for 1 hour or 19 hours, respectively.
HH1-DOTA bound to Alexa Fluor 488 is shown in green, Rituximab bound to Alexa Fluor 647 is shown in
magenta and Hoechst 33342 bound to DNA in the cell nucleus is shown in blue. 20 to 40 cells were scanned
for each treatment.
doi:10.1371/journal.pone.0128816.g007
Table 5. Maximum number of CD37 and CD20 antigens (Bmax) and equilibrium dissociation constant
(Kd) of
177Lu-HH1 and 125I-rituximab in Ramos cells.
Antibody (antigen) Kd (nM) Bmax (antigens/cell)
HH1 (CD37) 1.6 ± 1 128000 ± 40000
Rituximab (CD20) 2.4 ± 1 279000 ± 51000
Results presented as average ± standard deviation. N = 2 for rituximab, N = 3 for HH1.
doi:10.1371/journal.pone.0128816.t005
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177Lu-rituximab in femur and spleen was not correlated with the high uptake and retention in the
blood, but for myelotoxicity the cumulated activity in the bone marrow is more relevant than the
cumulated activity in the blood. The uptake and retention in bone marrow is probably estimated
better by the biodistribution data for femur than for blood. Another mechanism that might have
played a role for the difference in toxicity and therapeutic effect of 177Lu-rituximab and 177Lu-
HH1 is the difference in shaving of the antigen-antibody complex for CD20:rituximab and CD37:
HH1 [52,54]. Treatment with 177Lu-HH1 had a strong anti-tumor effect in the nude mice even
though the tumor uptake was inhomogeneous as shown in the SPECT/CT images. This result im-
plies that cross-fire effect might play an important role in the therapeutic effect of 177Lu-HH1.
The toxicity data presented indicates that the dose-limiting organ is the bone marrow, which
is in agreement with previous studies in mice and humans showing that the most common and
dose-limiting side effect of RIT is bone marrow toxicity [26,55]. The maximum tolerated activi-
ties (MTA) in nude mice can be assumed to be 550 MBq/kg = 1667 MBq/m2 for 177Lu-HH1
and 400 MBq/kg = 1212 MBq/m2 for 177Lu-rituximab (allometric equivalence performed on the
basis of Body Surface Area [56–60]). These values are in relatively good agreement with the clin-
ical MTA of 177Lu-rituximab found by Forrer et al. of 1665 MBq/m2 in humans [61].
CD37 internalizes, and has modest shedding in transformed B-cells expressing this antigen
[8,47]. The early studies with 131I-MB-1 have probably underestimated the potential of CD37
as target for RIT due to the use of a “non-residualizing” radiolabel. We have previously shown
that the use of the “residualizing” radiolabel 177Lu chelated via a DOTA linker to HH1 in-
creased the uptake of the RIC in tumor compared to the RIC 125I-HH1 up to 20 times [23].
This could at least partly be related to the accumulation of “residualizing” 177Lu inside the cells
due to the internalizing nature of CD37 [23].
In summary, 177Lu-HH1 is a promising RIC as treatment against CD37-expressing NHL
and the antitumor activity and the toxicity profile found in the preclinical studies supports fur-
ther clinical investigation.
Conclusion
This paper has shown, through comparisons of treatments of 177Lu-HH1, 177Lu-rituximab and
non-specific 177Lu-IgG1 isotype control in nude mice with subcutaneous Ramos lymphoma xe-
nografts, that 177Lu-HH1 has very promising properties as a treatment of NHL. 177Lu-HH1
considerably delayed tumor growth, increased the number of complete remissions and in-
creased the survival of nude mice. In addition, 177Lu-HH1 was less toxic than 177Lu-rituximab.
Based on these findings we conclude that 177Lu-HH1 is a promising agent for treatment of
NHL and clinical evaluation is recommended.
Supporting Information
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sisted in the design of the experiments presented in the paper.
(PDF)
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